Effect of VIVO (dipic-Cl) (H2O)2 on lipid metabolism disorders in the liver of STZ-induced diabetic rats

Journal of Diabetes Research

Volumn 2013, Issue , 2013, Pages

  Liu, Fang ^a   Xie, Mingxia ^a   Chen, Deliang ^a   Li, Jian ^a   Ding, Wenjun ^a  

^a UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN 1; FATTY ACID TRANSPORTER; FATTY ACID TRANSPORTER 5; LIPID; MESSENGER RNA; STREPTOZOCIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VANADIUM DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISORDERS OF LIPID METABOLISM; DRUG EFFECT; GENE EXPRESSION; LIPID LIVER LEVEL; LIVER FUNCTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; STREPTOZOCIN DIABETES;

EID: 84879404076     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2013/956737     Document Type: Article

References (56)

1. Daneman D., Type 1 diabetes. The Lancet 2006 367 9513 847 858 2-s2.0-33644841145 10.1016/S0140-6736(06)68341-4 (Pubitemid 43363372)
2. Wei D., Li M., Ding W., Effect of vanadate on gene expression of the insulin signaling pathway in skeletal muscle of streptozotocin-induced diabetic rats. Journal of Biological Inorganic Chemistry 2007 12 8 1265 1273 2-s2.0-35348888343 10.1007/s00775-007-0294-y (Pubitemid 47594266)
3. Dullaart R. P. F., Plasma lipoprotein abnormalities in type 1 (insulin-dependent) diabetes mellitus. Netherlands Journal of Medicine 1995 46 1 44 54 2-s2.0-0028870652 10.1016/0300-2977(94)00048-E
4. Erciyas F., Taneli F., Arslan B., Uslu Y., Glycemic control, oxidative stress, and lipid profile in children with type 1 diabetes mellitus. Archives of Medical Research 2004 35 2 134 140 2-s2.0-1542328919 10.1016/j.arcmed.2003.10. 002 (Pubitemid 38316832)
5. Gallou G., Ruelland A., Legras B., Maugendre D., Allannic H., Cloarec L., Plasma malondialdehyde in type 1 and type 2 diabetic patients. Clinica Chimica Acta 1993 214 2 227 234 2-s2.0-0027538569 10.1016/0009-8981(93)90114-J (Pubitemid 23102293)
6. Vergès B., Lipid disorders in type 1 diabetes. Diabetes and Metabolism 2009 35 5 353 360 10.1016/j.diabet.2009.04.004
7. Bechmann L. P., Hannivoort R. A., Gerken G., Hotamisligil G. S., Trauner M., Canbay A., The interaction of hepatic lipid and glucose metabolism in liver diseases. Journal of Hepatology 2012 56 4 952 964 10.1016/j.jhep.2011.08.025
8. Nishikawa S., Doi K., Nakayama H., Uetsuka K., The effect of fasting on hepatic lipid accumulation and transcriptional regulation of lipid metabolism differs between C57BL/6J and BALB/cA mice fed a high-fat diet. Toxicologic Pathology 2008 36 6 850 857 2-s2.0-54949115804 10.1177/0192623308323920
9. Bonen A., Campbell S. E., Benton C. R., Chabowski A., Coort S. L. M., Han X. X., Koonen D. P. Y., Glatz J. F. C., Luiken J. J. F. P., Regulation of fatty acid transport by fatty acid translocase/CD36. Proceedings of the Nutrition Society 2004 63 2 245 249 2-s2.0-2942719049 10.1079/PNS2004331 (Pubitemid 38787473)
10. Hamilton J. A., Fatty acid transport: difficult or easy? Journal of Lipid Research 1998 39 3 467 481 2-s2.0-0031921236 (Pubitemid 28158391)
11. Berk P. D., Regulatable fatty acid transport mechanisms are central to the pathophysiology of obesity, fatty liver, and metabolic syndrome. Hepatology 2008 48 5 1362 1376 2-s2.0-56149127703 10.1002/hep.22632
12. Abumrad N., Coburn C., Ibrahimi A., Membrane proteins implicated in long-chain fatty acid uptake by mammalian cells: CD36, FATP and FABPm. Biochimica et Biophysica Acta 1999 1441 1 4 13 2-s2.0-0032854610 10.1016/S1388-1981(99)00137-7 (Pubitemid 29469432)
13. Andersen M., Lenhard B., Whatling C., Erikssson P., Odeberg J., Alternative promoter usage of the membrane glycoprotein CD36. BMC Molecular Biology 2006 7 1, article 8 2-s2.0-33744946520 10.1186/1471-2199-7-8 (Pubitemid 43842129)
14. Su X., Abumrad N. A., Cellular fatty acid uptake: a pathway under construction. Trends in Endocrinology and Metabolism 2009 20 2 72 77 2-s2.0-63749108094 10.1016/j.tem.2008.11.001
15. Blaak E. E., Fatty acid metabolism in obesity and type 2 diabetes mellitus. Proceedings of the Nutrition Society 2003 62 3 753 760 2-s2.0-0141857891 10.1079/PNS2003290 (Pubitemid 37152861)
16. He J., Lee J. H., Febbraio M., Xie W., The emerging roles of fatty acid translocase/CD36 and the aryl hydrocarbon receptor in fatty liver disease. Experimental Biology and Medicine 2011 236 10 1116 1121 10.1258/ebm.2011.011128
17. Zhou J., Febbraio M., Wada T., Zhai Y., Kuruba R., He J., Lee J. H., Khadem S., Ren S., Li S., Silverstein R. L., Xie W., Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPAR γ in promoting steatosis. Gastroenterology 2008 134 2 556.e1 567.e1 2-s2.0-38649096259 10.1053/j.gastro.2007.11.037 (Pubitemid 351173049)
18. Pascussi J. M., Gerbal-Chaloin S., Duret C., Daujat-Chavanieu M., Vilarem M. J., Maurel P., The tangle of nuclear receptors that controls xenobiotic metabolism and transport: crosstalk and consequences. Annual Review of Pharmacology and Toxicology 2008 48 1 32 2-s2.0-41149153511 10.1146/annurev. pharmtox.47.120505.105349 (Pubitemid 351738147)
19. Ibrahimi A., Bonen A., Blinn W. D., Hajri T., Li X., Zhong K., Cameron R., Abumrad N. A., Muscle-specific overexpression of FAT/CD36 enhances fatty acid oxidation by contracting muscle, reduces plasma triglycerides and fatty acids, and increases plasma glucose and insulin. The Journal of Biological Chemistry 1999 274 38 26761 26766 2-s2.0-0033578604 10.1074/jbc.274.38.26761 (Pubitemid 29440012)
20. Wang G., He M., Yi P., Wang J., Li B., Li J., Fu Y., Bai L., Fu Q., Comparison of effects of vanadium absorbed by coprinus comatus with those of inorganic vanadium on bone in streptozotocin-diabetic rats. Biological Trace Element Research 2012 149 3 391 398 10.1007/s12011-012-9437-2
21. Wei Y. B., Yang X. D., Synthesis, characterization and anti-diabetic therapeutic potential of a new benzyl acid-derivatized kojic acid vanadyl complex. BioMetals 2012 25 6 1261 1268 10.1007/s10534-012-9587-x
22. Li M., Wei D., Ding W., Baruah B., Crans D. C., Anti-diabetic effects of cesium aqua (N,N′-ethylene(salicylideneiminato)-5-sulfonato) oxovanadium (IV) dihydrate in streptozotocin-induced diabetic rats. Biological Trace Element Research 2008 121 3 226 232 2-s2.0-44949110397 10.1007/s12011-007-8049-8
23. Clark T. A., Edel A. L., Heyliger C. E., Pierce G. N., Effective control of glycemic status and toxicity in Zucker diabetic fatty rats with an orally administered vanadate compound. Canadian Journal of Physiology and Pharmacology 2004 82 10 888 894 2-s2.0-13544262480 10.1139/y04-109 (Pubitemid 40223226)
24. Shisheva A., Shechter Y., Quercetin selectively inhibits insulin receptor function in vitro and the bioresponses of insulin and insulinomimetic agents in rat adipocytes. Biochemistry 1992 31 34 8059 8063 2-s2.0-0026722860
25. Degani H., Gochin M., Karlish S. J. D., Shechter Y., Electron paramagnetic resonance studies and insulin-like effects of vanadium in rat adipocytes. Biochemistry 1981 20 20 5795 5799 2-s2.0-0019788473 (Pubitemid 12217508)
26. Crans D. C., Yang L., Jakusch T., Kiss T., Aqueous chemistry of ammonium (dipicolinato)oxovanadate(V): the first organic vanadium(V) insulin-mimetic compound. Inorganic Chemistry 2000 39 20 4409 4416 2-s2.0-0034596940 10.1021/ic9908367
27. Crans D. C., Mahroof-Tahir M., Johnson M. D., Wilkins P. C., Yang L., Robbins K., Johnson A., Alfano J. A., Godzala M. E., Austin L. T., Willsky G. R., Vanadium(IV) and vanadium(V) complexes of dipicolinic acid and derivatives. Synthesis, X-ray structure, solution state properties: and effects in rats with STZ-induced diabetes. Inorganica Chimica Acta 2003 356 365 378 2-s2.0-10744221020 10.1016/S0020-1693(03)00430-4
28. Crans D. C., Smee J. J., Gaidamauskas E., Yang L., The chemistry and biochemistry of vanadium and the biological activities exerted by vanadium compounds. Chemical Reviews 2004 104 2 849 902 2-s2.0-1542378716 10.1021/cr020607t
29. Gupta D., Raju J., Prakash J., Baquer N. Z., Change in the lipid profile, lipogenic and related enzymes in the livers of experimental diabetic rats: effect of insulin and vanadate. Diabetes Research and Clinical Practice 1999 46 1 1 7 2-s2.0-0032853995 10.1016/S0168-8227(99)00067-4 (Pubitemid 29474995)
30. Li M., Ding W., Smee J. J., Baruah B., Willsky G. R., Crans D. C., Anti-diabetic effects of vanadium(III, IV, V)-chlorodipicolinate complexes in streptozotocin-induced diabetic rats. BioMetals 2009 22 6 895 905 2-s2.0-71349083092 10.1007/s10534-009-9241-4
31. Li M., Smee J. J., Ding W., Crans D. C., Anti-diabetic effects of sodium 4-amino-2,6-dipicolinatodioxovanadium(V) dihydrate in streptozotocin-induced diabetic rats. Journal of Inorganic Biochemistry 2009 103 4 585 589 2-s2.0-62349138112 10.1016/j.jinorgbio.2008.11.011
32. Smee J. J., Epps J. A., Ooms K., Bolte S. E., Polenova T., Baruah B., Yang L., Ding W., Li M., Willsky G. R., Chloro-substituted dipicolinate vanadium complexes: synthesis, solution, solid-state, and insulin-enhancing properties. Journal of Inorganic Biochemistry 2009 103 4 575 584 10.1016/j.jinorgbio.2008. 12.015
33. Ding W., Hasegawa T., Hosaka H., Peng D., Takahashi K., Seko Y., Effect of long-term treatment with vanadate in drinking water on KK mice with genetic non-insulin-dependent diabetes mellitus. Biological Trace Element Research 2001 80 2 159 174 2-s2.0-0034971435 10.1385/BTER:80:2:159 (Pubitemid 32548086)
34. Goldfine A. B., Simonson D. C., Folli F., Patti M. E., Kahn C. R., In vivo and in vitro studies of vanadate in human and rodent diabetes mellitus. Molecular and Cellular Biochemistry 1995 153 1-2 217 231 2-s2.0-0029618690 10.1007/BF01075941 (Pubitemid 26003387)
35. Leda M. O., Carlos D., Alcira M. C., Esther N. G., ALAS1 gene expression is down-regulated by Akt-mediated phosphorylation and nuclear exclusion of FOXO1 by vanadate in diabetic mice. Biochemical Journal 2012 442 2 303 310 10.1042/BJ20111005
36. Meyerovitch J., Rothenberg P., Shechter Y., Bonner-Weir S., Kahn C. R., Vanadate normalizes hyperglycemia in two mouse models of non-insulin-dependent diabetes mellitus. Journal of Clinical Investigation 1991 87 4 1286 1294 2-s2.0-0025779733
37. Xue J., Ding W., Liu Y., Anti-diabetic effects of emodin involved in the activation of PPAR γ on high-fat diet-fed and low dose of streptozotocin-induced diabetic mice. Fitoterapia 2010 81 3 173 177 2-s2.0-75849147916 10.1016/j.fitote.2009.08.020
38. Saeed M. K., Deng Y., Dai R., Attenuation of biochemical parameters in streptozotocin-induced diabetic rats by oral administration of extracts and fractions of Cephalotaxus sinensis. Journal of Clinical Biochemistry and Nutrition 2008 42 1 21 28 2-s2.0-39149083717 10.3164/jcbn.2008004 (Pubitemid 351252892)
39. Gylling H., Tuominen J. A., Koivisto V. A., Miettinen T. A., Cholesterol metabolism in type 1 diabetes. Diabetes 2004 53 9 2217 2222 2-s2.0-4344574435 10.2337/diabetes.53.9.2217 (Pubitemid 39145574)
40. Arkkila P. E. T., Koskinen P. J., Kantola I. M., Rönnemaa T., Seppänen E., Viikari J. S., Diabetic complications are associated with liver enzyme activities in people with type 1 diabetes. Diabetes Research and Clinical Practice 2001 52 2 113 118 2-s2.0-0035062624 10.1016/S0168-8227(00) 00241-2 (Pubitemid 32335604)
41. Zafar M., Naeem-ul-Hassan Naqvi S., Ahmed M., Kaim Khani Z. A., Altered liver morphology and enzymes in streptozotocin-induced diabetic rats. International Journal of Morphology 2009 27 3 719 725
42. Willsky G. R., Chi L. H., Liang Y., Gaile D. P., Hu Z., Crans D. C., Diabetes-altered gene expression in rat skeletal muscle corrected by oral administration of vanadyl sulfate. Physiological Genomics 2006 26 3 192 201 2-s2.0-33747373821 10.1152/physiolgenomics.00196.2005
43. Ohno T., Horio F., Tanaka S., Terada M., Namikawa T., Kitoh J., Fatty liver and hyperlipidemia in IDDM (insulin-dependent diabetes mellitus) of streptozotocin-treated shrews. Life Sciences 1999 66 2 125 131 2-s2.0-0033520882
44. Degirmenci I., Kalender S., Ustuner M. C., Kalender Y., Gunes H. V., Unal N., Basaran A., The effects of acarbose and Rumex patientia on liver ultrastructure in streptozotocin-induced diabetic (type II) rats. Drugs under Experimental and Clinical Research 2002 28 6 229 234 2-s2.0-0038242286 (Pubitemid 36596887)
45. Julius U., Influence of plasma free fatty acids on lipoprotein synthesis and diabetic dyslipidemia. Experimental and Clinical Endocrinology and Diabetes 2003 111 5 246 250 2-s2.0-0042178310 10.1055/s-2003-41284 (Pubitemid 37040104)
46. Boden G., Free fatty acids, insulin resistance, and type 2 diabetes mellitus. Proceedings of the Association of American Physicians 1999 111 3 241 248 2-s2.0-0033009862 10.1046/j.1525-1381.1999.99220.x (Pubitemid 29240904)
47. Kovacs P., Stumvoll M., Fatty acids and insulin resistance in muscle and liver. Best Practice and Research: Clinical Endocrinology and Metabolism 2005 19 4 625 635 2-s2.0-29244462992 10.1016/j.beem.2005.07.003 (Pubitemid 41819222)
48. Holloway G. P., Bezaire V., Heigenhauser G. J. F., Tandon N. N., Glatz J. F. C., Luiken J. J. F. P., Bonen A., Spriet L. L., Mitochondrial long chain fatty acid oxidation, fatty acid translocase/CD36 content and carnitine palmitoyltransferase I activity in human skeletal muscle during aerobic exercise. Journal of Physiology 2006 571 1 201 210 2-s2.0-33645892283 10.1113/jphysiol.2005.102178
49. Febbraio M., Abumrad N. A., Hajjar D. P., Sharma K., Cheng W., Pearce S. F. A., Silverstein R. L., A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. The Journal of Biological Chemistry 1999 274 27 19055 19062 2-s2.0-0033516477 10.1074/jbc.274.27.19055 (Pubitemid 29314101)
50. Sato O., Takanashi N., Motojima K., Third promoter and differential regulation of mouse and human fatty acid translocase/CD36 genes. Molecular and Cellular Biochemistry 2007 299 1-2 37 43 2-s2.0-34248659967 10.1007/s11010-005- 9035-0 (Pubitemid 46767536)
51. Luiken J. J. F. P., Arumugam Y., Bell R. C., Calles-Escandon J., Tandon N. N., Glatz J. F. C., Bonen A., Changes in fatty acid transport and transporters are related to the severity of insulin deficiency. The American Journal of Physiology 2002 283 3 E612 E621 2-s2.0-0036711133 (Pubitemid 35230500)
52. Goldberg I. J., Ginsberg H. N., Ins and outs modulating hepatic triglyceride and development of nonalcoholic fatty liver disease. Gastroenterology 2006 130 4 1343 1346 2-s2.0-33645978418 10.1053/j.gastro.2006. 02.040
53. Kamijo-Ikemori A., Sugaya T., Sekizuka A., Hirata K., Kimura K., Amelioration of diabetic tubulointerstitial damage in liver-type fatty acid-binding protein transgenic mice. Nephrology Dialysis Transplantation 2009 24 3 788 800 2-s2.0-60749134460 10.1093/ndt/gfn573
54. Chabowski A., Górski J., Luiken J. J. F. P., Glatz J. F. C., Bonen A., Evidence for concerted action of FAT/CD36 and FABPpm to increase fatty acid transport across the plasma membrane. Prostaglandins Leukotrienes and Essential Fatty Acids 2007 77 5-6 345 353 2-s2.0-36749103888 10.1016/j.plefa.2007.10.017 (Pubitemid 350214519)
55. Cheng Y., Liu G., Pan Q., Guo S., Yang X., Elevated expression of liver X receptor alpha (LXR α) in myocardium of streptozotocin-induced diabetic rats. Inflammation 2011 34 6 698 706 10.1007/s10753-010-9281-5
56. Harano Y., Yasui K., Toyama T., Nakajima T., Mitsuyoshi H., Mimani M., Hirasawa T., Itoh Y., Okanoue T., Fenofibrate, a peroxisome proliferator- activated receptor α agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver. Liver International 2006 26 5 613 620 2-s2.0-33646812161 10.1111/j.1478-3231.2006. 01265.x